Gainers
- PHAXIAM Therapeutics (NASDAQ:PHXM) stock rose 36.4% to $0.6 during Thursday's pre-market session. The market value of their outstanding shares is at $36.4 million.
- GRI Bio (NASDAQ:GRI) stock increased by 14.8% to $3.18. The market value of their outstanding shares is at $9.2 million.
- vTv Therapeutics (NASDAQ:VTVT) shares increased by 13.21% to $0.76. The market value of their outstanding shares is at $61.9 million.
- Vistagen Therapeutics (NASDAQ:VTGN) stock rose 12.01% to $7.88. The company's market cap stands at $62.9 million. As per the news, the Q1 earnings report came out today.
- Senti Biosciences (NASDAQ:SNTI) shares increased by 10.13% to $0.9. The company's market cap stands at $39.5 million.
- T2 Biosystems (NASDAQ:TTOO) stock increased by 10.1% to $0.38. The market value of their outstanding shares is at $109.4 million. As per the news, the Q2 earnings report came out 3 days ago.
Losers
- Galera Therapeutics (NASDAQ:GRTX) shares fell 82.9% to $0.38 during Thursday's pre-market session. The company's market cap stands at $16.4 million.
- Organogenesis Hldgs (NASDAQ:ORGO) stock decreased by 35.99% to $2.17. The company's market cap stands at $284.8 million. The company's, Q2 earnings came out yesterday.
- Matinas BioPharma Hldgs (AMEX:MTNB) stock decreased by 24.31% to $0.25. The market value of their outstanding shares is at $55.0 million. The company's, Q2 earnings came out yesterday.
- 180 Life Sciences (NASDAQ:ATNF) stock decreased by 21.81% to $0.66. The market value of their outstanding shares is at $3.5 million.
- Renovaro Biosciences (NASDAQ:RENB) stock decreased by 16.78% to $1.29. The market value of their outstanding shares is at $82.1 million.
- Certara (NASDAQ:CERT) stock fell 13.51% to $15.5. The market value of their outstanding shares is at $2.4 billion. As per the news, the Q2 earnings report came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.